Back to top

Amarin (AMRN) Gains As Market Dips: What You Should Know

Read MoreHide Full Article

In the latest trading session, Amarin (AMRN - Free Report) closed at $15.02, marking a +1.49% move from the previous day. This move outpaced the S&P 500's daily loss of 1.54%. At the same time, the Dow lost 1.49%, and the tech-heavy Nasdaq lost 2.17%.

Heading into today, shares of the biopharmaceutical company had lost 14.6% over the past month, lagging the Medical sector's loss of 6.36% and the S&P 500's loss of 6.77% in that time.

AMRN will be looking to display strength as it nears its next earnings release, which is expected to be February 26, 2019. The company is expected to report EPS of -$0.08, unchanged from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $66.47 million, up 23.38% from the year-ago period.

Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of -$0.33 per share and revenue of $218.37 million. These totals would mark changes of -32% and +20.57%, respectively, from last year.

Investors might also notice recent changes to analyst estimates for AMRN. These revisions typically reflect the latest short-term business trends, which can change frequently. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.

Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.

The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. AMRN is currently sporting a Zacks Rank of #3 (Hold).

The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 67, which puts it in the top 26% of all 250+ industries.

The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.




In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


Amarin Corporation PLC (AMRN) - free report >>

More from Zacks Tale of the Tape

You May Like

Published in